Xem mẫu
1 Epidemiology and Pathogenesis of Hepatocellular Carcinoma 15
51. Vineis P, Pirastu R (1997) Aromatic amines and cancer. Cancer Causes Control 8:346–355 52. Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific
N-nitrosamines. Chem Res Toxicol 11:559–603
53. Frei B, Forte TM, Ames BN, Cross CE (1991) Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J 277(Pt 1):133–138
54. Miro O, Alonso JR, Jarreta D, Casademont J, Urbano-Marquez A, Cardellach F (1999) Smoking disturbs mitochondrial respiratory chain function and enhances lipid peroxidation on human circulating lymphocytes. Carcinogenesis 20:1331–1336
55. Ueno Y (1985) The toxicology of mycotoxins. Crit Rev Toxicol 14:99–132
56. Guengerich FP, Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391–407
57. Guengerich FP, Shimada T, Iwasaki M, Butler MA, Kadlubar FF (1990) Activation of carcinogens by human liver cytochromes P-450. Basic Life Sci 53:381–396
58. Bulatao-Jayme J, Almero EM, Castro MC, Jardeleza MT, Salamat LA (1982) A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 11: 112–119
59. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE (1989) Hepatitis B virus, aflatox-ins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 49:2506–2509
60. Maheshwari S, Sarraj A, Kramer J, El-Serag HB (2007) Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 47:506–513
61. De B, V, Welsh JA, Yu MC, Bennett WP (1996) p53 mutations in hepatocellular carcinoma related to oral contraceptive use. Carcinogenesis 17:145–149
62. Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy–long-term follow-up of a Swedish cohort. Int J Cancer 67:327–332
63. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La VC (2003) Hormone replace-ment therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 105:408–412
64. Boffetta P, Matisane L, Mundt KA, Dell LD (2003) Meta-analysis of studies of occupational exposure to vinyl chloride in relation to cancer mortality. Scand J Work Environ Health 29:220–229
65. Dragani TA, Zocchetti C (2008) Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. Cancer Causes Control 19:1193–1200
66. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocel-lular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380
67. Bell DS, Allbright E (2007) The multifaceted associations of hepatobiliary disease and diabetes. Endocr Pract 13:300–312
68. Tolman KG, Fonseca V, Tan MH, Dalpiaz A (2004) Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 141:946–956
69. Harrison SA (2006) Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 40:68–76
70. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–539
71. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP et al (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47:1856–1862
72. Yuan JM, Govindarajan S, Arakawa K, Yu MC (2004) Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellularcarcinoma in blacks and whites in the U.S. Cancer 101:1009–1017
16 M.M. Hassan and A.O. Kaseb
73. YuMC,TongMJ,GovindarajanS,HendersonBE(1991) Nonviral riskfactorsforhepatocel-lular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 83:1820–1826
74. El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460–468
75. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL et al (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135:111–121
76. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL et al (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213
77. Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K et al (2007) Impact of dia-betes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 102:1939–1946
78. Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K et al (1998) Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 27:1567–1571
79. DellonES,ShaheenNJ(2005)Diabetesandhepatocellularcarcinoma:associations,biologic plausibility, and clinical implications. Gastroenterology 129:1132–1134
80. Bugianesi E (2005) Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther 22(Suppl 2):40–43
81. Moore MA, Park CB, Tsuda H (1998) Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 7:89–107
82. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A (2004) An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocar-cinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68:1003–1015
83. Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR (1997) Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 26:598–604
84. Tanaka S, Wands JR (1996) Insulin receptor substrate 1 overexpression in human hepatocel-lular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 56:3391–3394
85. Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S et al (2002) The major lipid peroxida-tion product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 23:1781–1789
86. Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290:G852–G858
87. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152
88. Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97:1005–1008
89. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM (2004) Obesity and hepatocellular carcinoma. Gastroenterology 127:S97–S103
90. Xu L, Han C, Lim K, Wu T (2006) Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res 66:11859–11868
91. Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470–477
92. Pucci E, Chiovato L, Pinchera A (2000) Thyroid and lipid metabolism. Int J Obes Relat Metab Disord 24(Suppl 2):S109–S112
93. Krotkiewski M (2000) Thyroid hormones and treatment of obesity. Int J Obes Relat Metab Disord 24(Suppl 2):S116–S119
1 Epidemiology and Pathogenesis of Hepatocellular Carcinoma 17
94. Dimitriadis G, Parry-Billings M, Bevan S, Leighton B, Krause U, Piva T et al (1997) The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats. Eur J Clin Invest 27:475–483
95. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183–1192
96. Liangpunsakul S, Chalasani N (2003) Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 37:340–343
97. Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN et al (2007) Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol 5:118–123
98. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK et al (2010) Duration of Diabetes and type of diabetes treatment, increase the risk of hepatocellular carcinoma. Cancer 116:1938–1946
99. Haffner SM (2000) Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resis-tance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord 24(Suppl 2):S56–S58
100. Hautanen A (2000) Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 24(Suppl 2):S64–S70
101. Hampl R, Kancheva R, Hill M, Bicikova M, Vondra K (2003) Interpretation of sex hormone-binding globulin levels in thyroid disorders. Thyroid 13:755–760
102. Tanaka K, Sakai H, Hashizume M, Hirohata T (2000) Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 60:5106–5110
103. ConteD,FraquelliM,FornariF,LodiL,BodiniP,BuscariniL(1999)Closerelationbetween cirrhosisandgallstones:cross-sectionalandlongitudinalsurvey.ArchInternMed159:49–52
104. Conte D, Barisani D, Mandelli C, Bodini P, Borzio M, Pistoso S et al (1991) Cholelithiasis in cirrhosis: analysis of 500 cases. Am J Gastroenterol 86:1629–1632
105. Fornari F, Civardi G, Buscarini E, Cavanna L, Imberti D, Rossi S et al (1990) Cirrhosis of the liver. A risk factor for development of cholelithiasis in males. Dig Dis Sci 35:1403–1408
106. Zhu JF, Shan LC, Chen WH (1994) [Changes in lipids, bilirubin and metal elements in the gallbladder bile in patients with cirrhosis of the liver]. Zhonghua Nei Ke Za Zhi 33:767–769
107. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC et al (2009) Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 49:116–123
108. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La VC et al (2002) Does coffee protect against hepatocellular carcinoma? Br J Cancer 87:956–959
109. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML et al (2005) Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 42:528–534
110. Tanaka K, Hara M, Sakamoto T, Higaki Y, Mizuta T, Eguchi Y et al (2007) Inverse associa-tion between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 98:214–218
111. TalaminiR,PoleselJ,MontellaM,DalML,CrispoA,TommasiLGetal(2006)Foodgroups and risk of hepatocellular carcinoma: a multicenter case-control study in Italy. Int J Cancer 119:2916–2921
112. Yu MW, Hsieh HH, Pan WH, Yang CS, Chen CJ (1995) Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 55:1301–1305
113. DemirG,BelentepeS,OzgurogluM,CelikAF,SayhanN,TekinSetal(2002)Simultaneous presentation of hepatocellular carcinoma in identical twin brothers. Med Oncol 19:113–116
114. Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM (2003) Segregation analysis of hepato-cellular carcinoma in a moderately high-incidence area of East China. World J Gastroenterol 9:2428–2432
18 M.M. Hassan and A.O. Kaseb
115. Zhang JY, Wang X, Han SG, Zhuang H (1998) A case-control study of risk fac-tors for hepatocellular carcinoma in Henan, China. Am J Trop Med Hyg 59: 947–951
116. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L et al (1999) Increased risk of hepatocellu-lar carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30:379–383
117. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ et al (2000) Familial risk of hepato-cellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 92:1159–1164
118. Chen CH, Huang GT, Lee HS, Yang PM, Chen DS, Sheu JC (1998) Clinical impact of screening first-degree relatives of patients with hepatocellular carcinoma. J Clin Gastroenterol 27:236–239
119. Yu MW, Chang HC, Chen PJ, Liu CJ, Liaw YF, Lin SM et al (2002) Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 31:1008–1015
120. Donato F, Gelatti U, Chiesa R, Albertini A, Bucella E, Boffetta P et al (1999) A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control 10:417–421
121. Piperno A (1998) Classification and diagnosis of iron overload. Haematologica 83:447–455 122. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A et al (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet
13:399–408
123. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R et al (1996) Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 22:187–194
124. Bullen JJ, Rogers HJ, Griffiths E (1978) Role of iron in bacterial infection. Curr Top Microbiol Immunol 80:1–35
125. Bullen JJ, Ward CG, Rogers HJ (1991) The critical role of iron in some clinical infections. Eur J Clin Microbiol Infect Dis 10:613–617
126. Miller M, Crippin JS, Klintmalm G (1996) End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis. Am J Gastroenterol 91:1427–1429
127. Hayashi H, Takikawa T, Nishimura N, Yano M (1995) Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22: 268–271
128. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A et al (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141–147
129. BonkovskyHL,BannerBF,RothmanAL(1997)Ironandchronicviralhepatitis.Hepatology 25:759–768
130. Sifers RN, Finegold MJ, Woo SL (1992) Molecular biology and genetics of alpha 1-antitrypsin deficiency. Semin Liver Dis 12:301–310
131. FabbrettiG,SergiC,ConsalesG,FaaG,BrisigottiM,RomeoGetal(1992) Geneticvariants of alpha-1-antitrypsin (AAT). Liver 12:296–301
132. Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 314:736–739
133. BlenkinsoppWK,HaffendenGP(1977)Alpha-1-antitrypsinbodiesintheliver.JClinPathol 30:132–137
134. Carlson J, Eriksson S (1985) Chronic ‘cryptogenic’ liver disease and malignant hepatoma in intermediate alpha 1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastroenterol 20:835–842
135. Zhou H, Fischer HP (1998) Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 22:742–748
136. TeckmanJH,QuD,PerlmutterDH(1996)Molecularpathogenesisofliverdiseaseinalpha1-antitrypsin deficiency. Hepatology 24:1504–1516
1 Epidemiology and Pathogenesis of Hepatocellular Carcinoma 19
137. BannerBF,KaramitsiosN,SmithL,BonkovskyHL(1998)Enhancedphenotypicexpression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol 93:1541–1545
138. Bianchi L (1993) Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152(Suppl 1):S63–S70
139. Siersema PD, ten Kate FJ, Mulder PG, Wilson JH (1992) Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 12:56–61
140. Cheng WS, Govindarajan S, Redeker AG (1992) Hepatocellular carcinoma in a case of Wilson’s disease. Liver 12:42–45
...
- tailieumienphi.vn
nguon tai.lieu . vn